Newcastle healthcare startup targets worldwide growth via seven-figure funding

ScubaTx Limited, a “pioneering” healthcare startup that has developed new technology to support organ transplantation, has raised £1.5m in funding, including investment led by the GMC Life Sciences Fund by Praetura and grant funding from Innovate UK.

ScubaTx will use the investment to enhance its designs and develop its device, as it looks to obtain the permissions to sell its products worldwide, with a specific focus on the UK, USA and mainland Europe and an initial eye on pancreatic procedures for patients with diabetes.

Founded in 2020, ScubaTx is a preclinical company that has developed a prototype organ transportation device that extends the time that human organs are viable for, with the goal of transforming organ transplant procedures worldwide.

The device utilises technology called ‘persufflation’ to deliver advanced organ preservation, by cooling donated organs and oxygenating tissues with humidified gas at tightly controlled pressures and flow rates. The company is now finalising mechanical tests and expects to begin pre-clinical trials in the next few weeks and pivotal clinical trials in the next year.

The company, which is a spinout from Newcastle University, has also announced plans to open an office in Greater Manchester as it looks to increase its UK footprint beyond the North East and continue its collaboration with several prestigious research organisations here in the UK, in mainland Europe and North America.

The round was led by GMC Life Sciences Fund by Praetura, a venture capital fund which invests in early-stage businesses and SMEs to boost life sciences innovation, which is managed by Praetura Ventures. The fund is also supported by the Greater Manchester Combined Authority, Cheshire & Warrington LEP and Bruntwood SciTech.

David Campbell, CEO of ScubaTx, commented: “I’m incredibly excited about the future of ScubaTx. Securing funding from the GMC Life Sciences Fund by Praetura and Innovate UK will now allow us to finalise our first commercial product and continue with our mission to transform the lives of organ patients worldwide.

“The capability of ScubaTx’s technology, as well as the depth of experience within the team, is immense, and this is what is giving us our strongest platform for growth. We’re deeply committed to improving lives, and this shines through in the team’s effort – the investment will help transform that effort into life-saving actions.”

Sim Singh-Landa, head of the GMC Life Sciences Fund by Praetura, added: “The strength of a fund like the GMC Life Sciences Fund by Praetura is that it enables the region to attract really inspiring businesses like ScubaTx, adding to the socio-economic prosperity of the local area and enabling the North West to continue cementing itself as a leader in life sciences.”

Dr William ‘Bill’ Scott, chief scientific officer of ScubaTx and senior lecturer at Newcastle University in Transplant and Regenerative Medicine, concluded: “I’m incredibly proud of the ScubaTx team and grateful to our investors for the opportunity to see this technology translate into clinical practice; positively impacting patient’s lives.”

By Matthew Neville – Senior Correspondent, Bdaily

• Add me on LinkedIn and Twitter to keep up to date
• And follow Bdaily on Facebook, Twitter and LinkedIn
• Submit press releases to editor@bdaily.co.uk for consideration.